Literature DB >> 16622092

The in vitro activity of selected defensins against an isolate of Pseudomonas in the presence of human tears.

A M McDermott1, D Rich, J Cullor, M J Mannis, W Smith, T Reid, C J Murphy.   

Abstract

BACKGROUND/AIMS: Pseudomonas aeruginosa is a major cause of severe bacterial keratitis and remains a difficult clinical entity to treat successfully with the current arsenal of antimicrobial agents. Defensins are small cationic peptides with broad in vitro antimicrobial activity and are potential ocular therapeutic agents. The authors characterised the in vitro activity of defensins NP-1 and NP-3a against P aeruginosa in the presence of human tears.
METHODS: A clinical Pseudomonas isolate was grown to mid-log phase, and 1 x 10(6 )colony forming units were exposed to the peptides (200 microg/ml) for up to 2 hours in the presence of varying concentrations (10-70%) of human tears.
RESULTS: For both peptides in the presence of 10% tears, >3 log units of killing was achieved within 30 minutes. In 70% tears, NP-1 produced >1 log unit of killing at 2 hours, indicating that, although reduced, its activity remained significant. In 20% tears, NP-3a demonstrated 2 log units of killing at 2 hours; however, the antimicrobial activity of this defensin was completely inhibited in the presence of 70% tears.
CONCLUSION: These in vitro data suggest that while the microbicidal activity of some defensins may be diminished at the ocular surface in vivo, significant activity is still possible with certain peptides.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16622092      PMCID: PMC1857073          DOI: 10.1136/bjo.2005.083428

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  20 in total

1.  Defensins and other antimicrobial peptides at the ocular surface.

Authors:  Alison M McDermott
Journal:  Ocul Surf       Date:  2004-10       Impact factor: 5.033

2.  Synergistic actions of antibacterial neutrophil defensins and cathelicidins.

Authors:  I Nagaoka; S Hirota; S Yomogida; A Ohwada; M Hirata
Journal:  Inflamm Res       Date:  2000-02       Impact factor: 4.575

3.  Effect of preservative-free artificial tears on the antimicrobial activity of human beta-defensin-2 and cathelicidin LL-37 in vitro.

Authors:  Ling C Huang; Daniele Jean; Alison M McDermott
Journal:  Eye Contact Lens       Date:  2005-01       Impact factor: 2.018

4.  Bacterial keratitis: a prospective clinical and microbiological study.

Authors:  F Schaefer; O Bruttin; L Zografos; Y Guex-Crosier
Journal:  Br J Ophthalmol       Date:  2001-07       Impact factor: 4.638

5.  Ulcerative keratitis in contact lens wearers.

Authors:  Ephigenia K Mela; Ioanna P Giannelou; John X Koliopoulos; Sotirios P Gartaganis; Koliopoulos X John; Gartaganis P Sotirios
Journal:  Eye Contact Lens       Date:  2003-10       Impact factor: 2.018

6.  Purification and antibacterial activity of antimicrobial peptides of rabbit granulocytes.

Authors:  M E Selsted; D Szklarek; R I Lehrer
Journal:  Infect Immun       Date:  1984-07       Impact factor: 3.441

7.  The use of antimicrobial peptides in ophthalmology: an experimental study in corneal preservation and the management of bacterial keratitis.

Authors:  Mark J Mannis
Journal:  Trans Am Ophthalmol Soc       Date:  2002

8.  Primary structures of six antimicrobial peptides of rabbit peritoneal neutrophils.

Authors:  M E Selsted; D M Brown; R J DeLange; S S Harwig; R I Lehrer
Journal:  J Biol Chem       Date:  1985-04-25       Impact factor: 5.157

9.  Modification of Pseudomonas aeruginosa interactions with corneal epithelial cells by human tear fluid.

Authors:  Suzanne M J Fleiszig; Mary S F Kwong; David J Evans
Journal:  Infect Immun       Date:  2003-07       Impact factor: 3.441

10.  Bacterial keratitis: predisposing factors, clinical and microbiological review of 300 cases.

Authors:  T Bourcier; F Thomas; V Borderie; C Chaumeil; L Laroche
Journal:  Br J Ophthalmol       Date:  2003-07       Impact factor: 4.638

View more
  8 in total

1.  In vitro studies on the antimicrobial peptide human beta-defensin 9 (HBD9): signalling pathways and pathogen-related response (an American Ophthalmological Society thesis).

Authors:  Harminder S Dua; Ahmad Muneer Otri; Andrew Hopkinson; Imran Mohammed
Journal:  Trans Am Ophthalmol Soc       Date:  2014-07

Review 2.  Peptide therapeutics for treating ocular surface infections.

Authors:  Curtis R Brandt
Journal:  J Ocul Pharmacol Ther       Date:  2014-09-24       Impact factor: 2.671

Review 3.  Role of host-defence peptides in eye diseases.

Authors:  Satya S Kolar; Alison M McDermott
Journal:  Cell Mol Life Sci       Date:  2011-05-17       Impact factor: 9.261

Review 4.  Dry eye disease and microbial keratitis: is there a connection?

Authors:  Srihari Narayanan; Rachel L Redfern; William L Miller; Kelly K Nichols; Alison M McDermott
Journal:  Ocul Surf       Date:  2013-01-29       Impact factor: 5.033

5.  Esculentin-1a(1-21)NH2: a frog skin-derived peptide for microbial keratitis.

Authors:  Satya Sree N Kolar; Vincenzo Luca; Hasna Baidouri; Giuseppe Mannino; Alison M McDermott; Maria Luisa Mangoni
Journal:  Cell Mol Life Sci       Date:  2014-08-03       Impact factor: 9.261

6.  Ocular surface expression and in vitro activity of antimicrobial peptides.

Authors:  Ling C Huang; Daniele Jean; Rita J Proske; Rose Y Reins; Alison M McDermott
Journal:  Curr Eye Res       Date:  2007 Jul-Aug       Impact factor: 2.424

7.  In vitro activity of human beta-defensin 2 against Pseudomonas aeruginosa in the presence of tear fluid.

Authors:  Ling C Huang; Rachel L Redfern; Srihari Narayanan; Rose Y Reins; Alison M McDermott
Journal:  Antimicrob Agents Chemother       Date:  2007-08-27       Impact factor: 5.191

8.  The Frog Skin-Derived Antimicrobial Peptide Esculentin-1a(1-21)NH2 Promotes the Migration of Human HaCaT Keratinocytes in an EGF Receptor-Dependent Manner: A Novel Promoter of Human Skin Wound Healing?

Authors:  Antonio Di Grazia; Floriana Cappiello; Akiko Imanishi; Arianna Mastrofrancesco; Mauro Picardo; Ralf Paus; Maria Luisa Mangoni
Journal:  PLoS One       Date:  2015-06-12       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.